mPharma set to launch new HPV DNA test kit
MPharma-Ghana is set to launch a new product for Human Papillomavirus (HPV) DNA Testing.
In addition to the launch of the new HPV DNA test kit, the pharmaceutical company is also seekin to create awareness on cervical cancer in commemoration of International Women’s Day (IWD). As such it will deliberate on the need for extensive cervical cancer awareness.
Speaking on the launch of the new product, the Managing Dirrector of mPharma Ghana Emmanuel Agyei described cervical cancer as disease that is of utmost concern especially in Africa.
He said “we believe that the global confrontation with COVID-19 has increased resources in molecular diagnostics – a feat championed by mPharma. And that its (COVID-19) gradual recession should challenge us to fully redeploy these facilities into efficient use, especially in the diagnoses of other prevailing infectious diseases.”
“A notable disease that is of utmost concern among others is cervical cancer. Globally, cervical cancer is the fourth most common cancer amongst women. In Africa, it comes second to breast cancer.” he added.
Mr Agyei went further to explain the importance of testing in order to promote an effective rollout of vaccines.
He stated, “onset precancerous or cancerous lesions are treatable; therefore, early detection amongst high-risk middle-aged women will inform effective treatment options. Furthermore, there exist potential vaccines that may offer long-term protection. Therefore, testing is necessary and could facilitate the effective rollout of these vaccines.”
mPharma stocks highly sensitive real-time PCR-based HPV DNA testing kits and is offering 10,000 free tests to support women in Ghana and Nigeria to know their statuses through an mPharma led project captured as the ‘Ten Thousand Women Initiative (TTWI)’.
In addition, visual inspection by acetic acid (VIA) and colposcopy are being used to assess infected women further to offer appropriate treatment to those with precancerous lesions.
Source: Ghana News
